Abstracts tagged "rheumatoid arthritis (RA) and tofacitinib"

Abstract Number: 559 • 2015 ACR/ARHP Annual Meeting
Herpes Zoster and Tofacitinib: The Risk of Concomitant Nonbiologic Therapy
Kevin L. Winthrop¹, Jeffrey R. Curtis², Stephen Lindsey³, Hernan Valdez⁴, Haiyun Fan⁵, Lisy Wang⁶, Alan M. Mendelsohn⁵ and Eustratios Bananis⁵, ¹Oregon Health & Science University, Portland, OR, ²The University of Alabama at Birmingham, Birmingham, AL, ³Ochsner Medical Center, Baton Rouge, LA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Patients with RA are at increased risk for herpes zoster (HZ). Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Treatment…
Abstract Number: 566 • 2015 ACR/ARHP Annual Meeting
Genome-Wide Trans-Ancestry Meta-Analysis of Herpes Zoster in RA and Pso Patients Treated with Tofacitinib
Nan Bing¹, HuanYu Zhou¹, BaoHong Zhang¹, John D Bradley², Makoto Nagaoka³, Hernan Valdez⁴, Michael Vincent¹ and James D. Clark¹, ¹Pfizer Inc, Cambridge, MA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Tokyo, Japan, ⁴Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Rates of herpes zoster (HZ) were higher than observed with…
Abstract Number: 571 • 2015 ACR/ARHP Annual Meeting
Malignancy Data in Tofacitinib-Treated Japanese Patients with Rheumatoid Arthritis
Yoshiya Tanaka¹, Tsutomu Takeuchi², Hisashi Yamanaka³, Naonobu Sugiyama M.D., Ph.D⁴, Takunari Yoshinaga⁴, Kanae Togo⁴, Jamie Geier⁵, Mary Boy⁵ and Carol Connell⁵, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Tokyo Women’s Medical University, Tokyo, Japan, ⁴Pfizer Japan Inc, Tokyo, Japan, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). In the global tofacitinib RA clinical program, rates and types…
Abstract Number: 1225 • 2015 ACR/ARHP Annual Meeting
Long-Term Use of Biological Therapy and Discontinuation Rates in Rheumatoid Arthritis – Real World Patient Data
Laurent Chanroux, Joan Casellas and Fara Mboge, Therapy Watch, Research Partnership, London, United Kingdom
Background/Purpose: Biologics (bDMARDs) have been shown to control disease progression in RA however there is still no cure for the disease and in many cases…
Abstract Number: 2910 • 2014 ACR/ARHP Annual Meeting
Tofacitinib Facilitates the Expansion of Myeloid-Derived Suppressor Cells and Ameliorates Arthritis in SKG Mice
Keisuke Nishimura¹, Jun Saegusa¹, Fumichika Matsuki², Kengo Akashi¹, Goichi Kageyama¹ and Akio Morinobu¹, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells that are characterized by the co-expression of Gr1 and CD11b in mice. MDSCs suppress…
Abstract Number: 1908 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcomes in the Tofacitinib RA Safety Database through April 2014
A. Marren¹, Y. Chen¹, D. Frazier² and J. Geier³, ¹Pfizer Inc, Collegeville, PA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Its effect in pregnant women is of interest, as tofacitinib…
Abstract Number: 486 • 2014 ACR/ARHP Annual Meeting
Tofacitinib Improves Arterial Stiffness Despite up-Regulating Serum Cholesterol with Chronic Cardiovascular Disease in Methotrexate-Resistant Active Rheumatoid Arthritis Patients. a Cohort Study
Kensuke Kume¹, Kanzo Amano², Susumu Yamada², Toshikatsu Kanazawa³, Hiroshi Komori⁴, Kazuhiko Hatta⁵, Kuniki Amano⁶ and Noriko Kuwaba⁷, ¹20-16 Higashi Kannon, Nishi Ward, hiroshima clinic, Hiroshima, Japan, ²Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ³rheumatology, hiroshima clinic, hiroshima, Japan, ⁴internal medicine, hiroshima clinic, hiroshima, Japan, ⁵Rheumatology, Hatta Clinic, Kure, Japan, ⁶Rheumatology, Sky Clinic, Hiroshima, Japan, ⁷Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased cardiovascular (CV) risk. We should have strategies for primary cardiovascularprevention in RA. Tofacitinib (Tofa) could possibly…
Abstract Number: L9 • 2013 ACR/ARHP Annual Meeting
Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naïve Patients with Rheumatoid Arthritis: Radiographic, Clinical and Functional Comparison
Roy Fleischmann¹, E. B. Lee², S Hall³, B. E. Wilkinson⁴, John D. Bradley⁵, D. Gruben⁴, T. Koncz⁶, S. Krishnaswami⁷, G. Wallenstein⁶, S. H. Zwillich⁴ and R.F. van Vollenhoven⁸, ¹Metroplex Clinical Research Center, Dallas, TX, ²Seoul National University, Seoul, South Korea, ³Cabrini Health and Monash University, Melbourne, Australia, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc., Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Clinical Pharmacology, Pfizer Inc, Groton, CT, ⁸The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of RA. This Phase 3, 24-mo study (ORAL Start; NCT01039688) compared efficacy, including inhibition…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.